Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients

URN:NBN:SI:doc-I9CLKMOC2022Devjak, RokEdelbaher, NatalijaJanžič, UrškaJerič, TinaOsrajnik, IlonkaTurnšek, NinaUnk, MojcaVidovič, Dušankadocuments/doc/I/URN_NBN_SI_doc-I9CLKMOC_001.pdfdocuments/doc/I/URN_NBN_SI_doc-I9CLKMOC_001.txt356articlestr. 371-37910.2478/raon-2022-00251187932191318-2099URN:NBN:SI:doc-I9CLKMOCengAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)BYepidermal growth factor receptorklinične študijelung cancernedrobnocelični raknon-small cell lung cancerrak pljučreal-world studyreceptor epidermalnega rastnega faktorjaReal-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patientstreated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study